Stem cell research hits the French political agenda
This article was originally published in Clinica
Executive Summary
Embyronic stem cell research has risen to the top of the French political agenda, one month after both Houses of the UK Parliament voted in favour of using this ethically sensitive technique (see Clinica No 943, p 5). But with a presidential election next year, the French politicians are treating the delicate subject with extreme caution. As the President, Jacques Chirac, and the Prime Minister, Lionel Jospin, represent opposing views, the parliamentary debate could be long and slow.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.